This invention belongs to the field of
probiotic screening and application technology, specifically relating to a strain of *
Lactobacillus rhamnosus* and its application in the prevention and treatment of
colon polyps and colon
cancer. The *
Lactobacillus rhamnosus* is named *
Lactobacillus rhamnosus* (…). Lacticaseibacillus rhamnosus S28, deposited on January 15, 2026, at the China Center for Type Culture Collection (CCTCC), Wuhan University, Wuhan, China, with accession number CCTCC NO: M2026129, exhibits strong inhibitory activity against *
Streptococcus bovis* and demonstrates a strong
agglutination effect with it. It can be used to prevent or treat colonic polyps and colon
cancer caused by *
Streptococcus bovis*. This invention also provides
probiotic pellets containing *
Lactobacillus rhamnosus* S28, which exhibit strong resistance, effectively protecting the probiotics from
gastric digestion, ensuring their smooth arrival in the intestines, and achieving rapid disintegration within the intestines, showing broad market prospects.